Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Examination of ADMA (Asymmetric-dimethylarginine)-Serum Level and DDAH II (Dimethylarginine Dimethylaminohydrolase)- Polymorphism in Patients With Severe Sepsis and Septic Shock as Prognostic Value

NCT01632059 is registered in ClinicalTrials.gov with Universitätsklinikum Hamburg-Eppendorf as lead sponsor.

NCT NCT01632059
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01632059 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Examination of ADMA (Asymmetric-dimethylarginine)-Serum Level and DDAH II (Dimethylarginine Dimethylaminohydrolase)- Polymorphism in Patients With Severe Sepsis and Septic Shock as Prognostic Value
Lead sponsor
Universitätsklinikum Hamburg-Eppendorf
Phase
Observational
Overall status
Completed
Start date
February 29, 2012
Completion date
April 30, 2017
Enrollment
120 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sepsis, septic shock